Researchers at the Arc Institute have developed and optimized bridge recombinases, versatile RNA-guided enzymes capable of large-scale genome rearrangements in human cells at efficiencies up to 20%. This breakthrough surpasses traditional gene editing tools by enabling precise insertion, deletion, or inversion of DNA segments up to megabase size—vastly larger genomic regions than typical CRISPR systems manage. Such advancements open new therapeutic possibilities for genetic disorders requiring complex genome restructuring and represent a major paradigm shift in genome engineering.